Clinical trials with bleomycin in lymphomas and in solid tumors

G. Bonadonna, M. de Lena, S. Monfardini, C. Bartoli, E. Bajetta, G. Beretta, F. Fossati-Bellani

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

The authors report the results of Phase I and Phase II evaluation of intravenous bleomycin (BLM) in 176 patients. During the trial different doses and schedules were employed. The less toxic regimen was that of 15 mg/m2 × 2/week per 4 weeks. Irrespective of the schedules, the side effects are represented by sclerotic changes of the skin of hands (88%), skin hyperpigmentation (78%), fever (70%), loss of hair (68%), stomatitis (47%) pulmonary toxicity (42%), gastro-intestinal symptoms (20%). No significant myelo-suppression was observed. Pulmonary toxicity occurred after 4-10 weeks from starting therapy and was detected on clinical bases (fine crepitations at the base), radiologically (reticulonodularity mostly at the lower lung zones) and histologically (edema of alveoli, hyaline membranes formation, collagen deposition). Upon prompt discontinuation of BLM, the signs of pulmonary damage remained unchanged or regressed in the majority of cases. Lower total doses of BLM produced a lesser incidence of lung toxicity. However, in about 5% of cases the presumptive cause of death could be related to extensive pulmonary drug-induced lesions. The incidence of lung toxicity was not found to be significantly related to the age of patients, to the total dose of BLM or to the presence of chronic pulmonary disease. BLM produced significant regression in all types of malignant lymphomas (40%), in epidermoid carcinomas of the head and neck (57%) and of the esophagus (60%). No significant responses were observed in epidermoid carcinomas of the lung. Regressions were prompt but usually short-lived with or without maintenance therapy. Because of its toxic and therapeutic properties BLM appears suitable for therapeutic trials either in short courses alone in or in combination with myelosuppressive agents.

Original languageEnglish
JournalEuropean Journal of Cancer (1965)
Volume8
Issue number2
DOIs
Publication statusPublished - 1972

Fingerprint

Lymphoma
Clinical Trials
Bleomycin
Lung
Neoplasms
Poisons
Squamous Cell Carcinoma
Appointments and Schedules
Skin
Stomatitis
Hyperpigmentation
Hyalin
indium-bleomycin
Alopecia
Incidence
Therapeutics
Esophagus
Lung Diseases
Cause of Death
Edema

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Bonadonna, G., de Lena, M., Monfardini, S., Bartoli, C., Bajetta, E., Beretta, G., & Fossati-Bellani, F. (1972). Clinical trials with bleomycin in lymphomas and in solid tumors. European Journal of Cancer (1965), 8(2). https://doi.org/10.1016/0014-2964(72)90045-X

Clinical trials with bleomycin in lymphomas and in solid tumors. / Bonadonna, G.; de Lena, M.; Monfardini, S.; Bartoli, C.; Bajetta, E.; Beretta, G.; Fossati-Bellani, F.

In: European Journal of Cancer (1965), Vol. 8, No. 2, 1972.

Research output: Contribution to journalArticle

Bonadonna, G, de Lena, M, Monfardini, S, Bartoli, C, Bajetta, E, Beretta, G & Fossati-Bellani, F 1972, 'Clinical trials with bleomycin in lymphomas and in solid tumors', European Journal of Cancer (1965), vol. 8, no. 2. https://doi.org/10.1016/0014-2964(72)90045-X
Bonadonna, G. ; de Lena, M. ; Monfardini, S. ; Bartoli, C. ; Bajetta, E. ; Beretta, G. ; Fossati-Bellani, F. / Clinical trials with bleomycin in lymphomas and in solid tumors. In: European Journal of Cancer (1965). 1972 ; Vol. 8, No. 2.
@article{7e42a555daca46498102bcf0929ef36c,
title = "Clinical trials with bleomycin in lymphomas and in solid tumors",
abstract = "The authors report the results of Phase I and Phase II evaluation of intravenous bleomycin (BLM) in 176 patients. During the trial different doses and schedules were employed. The less toxic regimen was that of 15 mg/m2 × 2/week per 4 weeks. Irrespective of the schedules, the side effects are represented by sclerotic changes of the skin of hands (88{\%}), skin hyperpigmentation (78{\%}), fever (70{\%}), loss of hair (68{\%}), stomatitis (47{\%}) pulmonary toxicity (42{\%}), gastro-intestinal symptoms (20{\%}). No significant myelo-suppression was observed. Pulmonary toxicity occurred after 4-10 weeks from starting therapy and was detected on clinical bases (fine crepitations at the base), radiologically (reticulonodularity mostly at the lower lung zones) and histologically (edema of alveoli, hyaline membranes formation, collagen deposition). Upon prompt discontinuation of BLM, the signs of pulmonary damage remained unchanged or regressed in the majority of cases. Lower total doses of BLM produced a lesser incidence of lung toxicity. However, in about 5{\%} of cases the presumptive cause of death could be related to extensive pulmonary drug-induced lesions. The incidence of lung toxicity was not found to be significantly related to the age of patients, to the total dose of BLM or to the presence of chronic pulmonary disease. BLM produced significant regression in all types of malignant lymphomas (40{\%}), in epidermoid carcinomas of the head and neck (57{\%}) and of the esophagus (60{\%}). No significant responses were observed in epidermoid carcinomas of the lung. Regressions were prompt but usually short-lived with or without maintenance therapy. Because of its toxic and therapeutic properties BLM appears suitable for therapeutic trials either in short courses alone in or in combination with myelosuppressive agents.",
author = "G. Bonadonna and {de Lena}, M. and S. Monfardini and C. Bartoli and E. Bajetta and G. Beretta and F. Fossati-Bellani",
year = "1972",
doi = "10.1016/0014-2964(72)90045-X",
language = "English",
volume = "8",
journal = "European Journal of Cancer",
issn = "0014-2964",
publisher = "Elsevier Ltd",
number = "2",

}

TY - JOUR

T1 - Clinical trials with bleomycin in lymphomas and in solid tumors

AU - Bonadonna, G.

AU - de Lena, M.

AU - Monfardini, S.

AU - Bartoli, C.

AU - Bajetta, E.

AU - Beretta, G.

AU - Fossati-Bellani, F.

PY - 1972

Y1 - 1972

N2 - The authors report the results of Phase I and Phase II evaluation of intravenous bleomycin (BLM) in 176 patients. During the trial different doses and schedules were employed. The less toxic regimen was that of 15 mg/m2 × 2/week per 4 weeks. Irrespective of the schedules, the side effects are represented by sclerotic changes of the skin of hands (88%), skin hyperpigmentation (78%), fever (70%), loss of hair (68%), stomatitis (47%) pulmonary toxicity (42%), gastro-intestinal symptoms (20%). No significant myelo-suppression was observed. Pulmonary toxicity occurred after 4-10 weeks from starting therapy and was detected on clinical bases (fine crepitations at the base), radiologically (reticulonodularity mostly at the lower lung zones) and histologically (edema of alveoli, hyaline membranes formation, collagen deposition). Upon prompt discontinuation of BLM, the signs of pulmonary damage remained unchanged or regressed in the majority of cases. Lower total doses of BLM produced a lesser incidence of lung toxicity. However, in about 5% of cases the presumptive cause of death could be related to extensive pulmonary drug-induced lesions. The incidence of lung toxicity was not found to be significantly related to the age of patients, to the total dose of BLM or to the presence of chronic pulmonary disease. BLM produced significant regression in all types of malignant lymphomas (40%), in epidermoid carcinomas of the head and neck (57%) and of the esophagus (60%). No significant responses were observed in epidermoid carcinomas of the lung. Regressions were prompt but usually short-lived with or without maintenance therapy. Because of its toxic and therapeutic properties BLM appears suitable for therapeutic trials either in short courses alone in or in combination with myelosuppressive agents.

AB - The authors report the results of Phase I and Phase II evaluation of intravenous bleomycin (BLM) in 176 patients. During the trial different doses and schedules were employed. The less toxic regimen was that of 15 mg/m2 × 2/week per 4 weeks. Irrespective of the schedules, the side effects are represented by sclerotic changes of the skin of hands (88%), skin hyperpigmentation (78%), fever (70%), loss of hair (68%), stomatitis (47%) pulmonary toxicity (42%), gastro-intestinal symptoms (20%). No significant myelo-suppression was observed. Pulmonary toxicity occurred after 4-10 weeks from starting therapy and was detected on clinical bases (fine crepitations at the base), radiologically (reticulonodularity mostly at the lower lung zones) and histologically (edema of alveoli, hyaline membranes formation, collagen deposition). Upon prompt discontinuation of BLM, the signs of pulmonary damage remained unchanged or regressed in the majority of cases. Lower total doses of BLM produced a lesser incidence of lung toxicity. However, in about 5% of cases the presumptive cause of death could be related to extensive pulmonary drug-induced lesions. The incidence of lung toxicity was not found to be significantly related to the age of patients, to the total dose of BLM or to the presence of chronic pulmonary disease. BLM produced significant regression in all types of malignant lymphomas (40%), in epidermoid carcinomas of the head and neck (57%) and of the esophagus (60%). No significant responses were observed in epidermoid carcinomas of the lung. Regressions were prompt but usually short-lived with or without maintenance therapy. Because of its toxic and therapeutic properties BLM appears suitable for therapeutic trials either in short courses alone in or in combination with myelosuppressive agents.

UR - http://www.scopus.com/inward/record.url?scp=0015330046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0015330046&partnerID=8YFLogxK

U2 - 10.1016/0014-2964(72)90045-X

DO - 10.1016/0014-2964(72)90045-X

M3 - Article

VL - 8

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0014-2964

IS - 2

ER -